quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:05:00·28d
PRRelease
Crinetics Pharmaceuticals Inc. logo

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

CRNX· Crinetics Pharmaceuticals Inc.
Health Care
Original source

Companies

  • CRNX
    Crinetics Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Jan 12UpdateGoldman$67.00
  • Jul 10UpdateGoldman$36.00
  • Mar 25UpdateStifel$60.00
  • Feb 11UpdateTD Cowen-
  • Feb 4UpdateWolfe Research-
  • Jan 22UpdateJefferies$55.00

Related

  • PR8d
    Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer
  • INSIDER13d
    SEC Form 4 filed by Knight Jeff E.
  • SEC13d
    Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits
  • PR15d
    Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.
  • SEC31d
    SEC Form 8-K filed by Crinetics Pharmaceuticals Inc.
  • INSIDER36d
    SEC Form 4 filed by Crinetics Pharmaceuticals Inc.
  • INSIDER36d
    SEC Form 4 filed by Knight Jeff E.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022